Related news from
Mon, 06 May 2024 11:15:03 +0000	Investors Pile Into Amgen in Search of Next Obesity Drug Payout (Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeJudge Threatens Trump With Jail Over Gag Order ViolationsTreasury Rally Risks Running Into a $125 Billion Brick WallBuffett Praises Apple After Trimming It, Drops Paramount StakeThe shares s
Sat, 04 May 2024 13:26:09 +0000	Amgen First Quarter 2024 Earnings: EPS Misses Expectations Amgen ( NASDAQ:AMGN ) First Quarter 2024 Results Key Financial Results Revenue: US$7.45b (up 22% from 1Q 2023). Net...
Sat, 04 May 2024 05:03:41 +0000	Decoding Amgen Inc (AMGN): A Strategic SWOT Insight Insightful Analysis of Amgen Inc's Strengths, Weaknesses, Opportunities, and Threats
Fri, 03 May 2024 22:15:34 +0000	Why Amgen Stock Zoomed Nearly 12% Higher Today The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
Fri, 03 May 2024 21:07:25 +0000	Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Fri, 03 May 2024 20:51:00 +0000	These Stocks Moved the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.
Fri, 03 May 2024 20:04:21 +0000	Amgen Is 'Very Encouraged' With Its Obesity Drug. But Can It Take On Novo, Lilly Duopoly? Amgen stock neared its record high Friday after the company said it's "very encouraged" with midstage test results for its obesity treatment.
Fri, 03 May 2024 18:53:08 +0000	Analyst unveils Amgen stock price target after weight-loss drug data Here's what could happen next to Amgen shares.
Fri, 03 May 2024 17:00:32 +0000	Interest rate cuts could switch ‘from stroll to a sprint’ after US jobs surprise Traders have pulled forward their expectations for the first interest rate cuts in the US as the economy added fewer jobs than expected.
Fri, 03 May 2024 16:26:55 +0000	Stocks to Watch Friday: Amgen, Apple, Exxon **Apple (AAPL)**: The iPhone maker authorized $110 billion in stock buybacks and forecast a return to revenue growth in the current quarter. Apple shares climbed more than 6%. **Amgen (AMGN)**: The drug manufacturer's chief executive said he was “very encouraged” by early data for its experimental obesity treatment.
Fri, 03 May 2024 16:15:47 +0000	Dow Jones Jumps 400 Points As Apple Stock Surges; Nvidia Jumps Again, Tempts New Buyers A weak April jobs report fueled a wave of buying in the stock market today. Apple and Amgen were strong gainers in the Dow Jones.
Fri, 03 May 2024 16:14:34 +0000	Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
Fri, 03 May 2024 16:13:34 +0000	US STOCKS-Wall St rallies after soft jobs data allays rate jitters Wall Street's main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen also helped. U.S. job growth slowed more than expected in April and the increase in annual wages fell below 4% for the first time in nearly three years.
Fri, 03 May 2024 15:48:00 +0000	Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
Fri, 03 May 2024 15:35:26 +0000	Weight-loss drug competition heats up. Is Wegovy in trouble? The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Fri, 03 May 2024 15:23:59 +0000	Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript May 2, 2024 Amgen Inc. beats earnings expectations. Reported EPS is $3.96, expectations were $3.88. Amgen Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: My name is Julianne, and I will […]
Fri, 03 May 2024 14:51:00 +0000	Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying. Amgen’s progress on its experimental weight-loss drug offered investors a reminder that Novo Nordisk isn’t the only game in town. Amgen’s jumped some 13%. Amgen late Thursday gave some brief but bullish commentary on its drug candidate, MariTide.
Fri, 03 May 2024 14:42:00 +0000	Amgen Stock Is Having Its Best Day Since 2009. Why Wall Street Is Excited About Its Weight-Loss Drug. The company is trying to carve a niche in a rapidly growing obesity-drug market that’s currently dominated by Eli Lilly and Novo Nordisk.
Fri, 03 May 2024 14:31:07 +0000	US STOCKS-Wall St gains after soft jobs data allays rate jitters Wall Street's main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen on upbeat corporate updates added support. U.S. job growth slowed more than expected in April and the increase in annual wages fell below 4% for the first time in nearly three years, while the unemployment rate stood at 3.9% compared with expectations that it would remain steady at 3.8%.
Fri, 03 May 2024 14:11:06 +0000	Amgen surges over confidence in early obesity drug results Shares of Amgen (AMGN) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development to treat obesity. The pharmaceutical giant beat first-quarter revenue estimates while reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins The Morning Brief to break down the latest developments from Amgen and its outlook on use cases for the drug in question, MariTide. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino